News
Events
Press Releases
Contact Us
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
Rizaport
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
Rizaport
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
INTELGENX
Home
>
Investors
>
Press Releases
INTELGENX
Home
>
Investors
>
Press Releases
Normal
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
IntelGenx Reports Results for the Nine Months Ended September 30, 2008
November 12, 2008
IntelGenx Corp. set to file NDA for antidepressant
October 10, 2008
IntelGenx Welcomes New Chief Financial Officer, Paul Simmons
September 5, 2008
IntelGenx Corp. and Cary Pharmaceuticals Inc. Announce Successful End-of-Phase II Meeting with FDA for Development of their Antidepressant CPI-300
July 30, 2008
IntelGenx Technologies Corp. Engages Auctus Capital Partners Inc. To Perform Investor Relations Activities
June 3, 2008
IntelGenx Technologies Corp. Approved for trading on the TSX-Venture Exchange
May 22, 2008
IntelGenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion
April 14, 2008
IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant
April 7, 2008
IntelGenx Technologies Corp. announces closing of private placement
March 28, 2008
IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million
January 7, 2008
Home
About Us
Overview
Management
Board of Directors
Scientific Advisory Board
Careers
Product
Overview
Rizaport
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
VetaFilm
Services
Manufacturing Services
Overview
Manufacturing & Packaging
Services
Partnering
Overview
Trade Shows
BD Contacts
Investors
Overview
Shareholder Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
XBRL Files
Analyst Coverage
Videos
RSS Feeds
IR Contact
Shareholder Tools
Financial Reports
E-mail Alerts
RSS News Feeds
About us
Overview
Management
Board of Directors
Careers
Product
Overview
Rizaport
Tadalafil
Loxapine
Montelukast
More Products
R&D Services
Overview
VersaFilm
Services
Manufacturing Services
Overview
Film Manufacturing
Services
Partnering
Overview
Investors
Overview
Financial Reports
Corporate Governance
Press Releases
Stock Price
Presentations
Regulatory Filings
Analyst Coverage
IR Contact
More Links
Facebook
Twitter
Linkedin
Contact us
Careers
Email Signup
RSS Feeds
© Copyright 2017. IntelGenx Corp. All Rights Reserved.
Terms of Service
Privacy
Contact Us
Powered By Q4 Inc.
5.15.0.14